{"id":"NCT01210352","sponsor":"Endo Pharmaceuticals","briefTitle":"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects","officialTitle":"An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12-13","primaryCompletion":"2017-10-06","completion":"2017-10-06","firstPosted":"2010-09-28","resultsPosted":"2019-05-07","lastUpdate":"2021-08-20"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post Operative Pain"],"interventions":[{"type":"DRUG","name":"oxymorphone HCl","otherNames":["Opana"]}],"arms":[{"label":"CII Drug","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic for acute postoperative pain in pediatric subjects.\n\nThis post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer promotes opioids and no longer markets Opana® ER.","primaryOutcome":{"measure":"Pain Intensity Score of Oxymorphone IR Oral Liquid in Pediatric Subjects by Age Group and Time Points in Single Dose Phase","timeFrame":"Baseline, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose; and at the time of rescue","effectByArm":[{"arm":"6 Years to ≤ 12 Years Age Group in Single Dose Phase","deltaMin":4.5,"sd":3.12},{"arm":"2 Years to < 6 Years Age Group in Single Dose Phase","deltaMin":3.4,"sd":3.55},{"arm":"0 Years to < 2 Years Age Group in Single Dose Phase","deltaMin":2.4,"sd":1.9}],"pValues":[]},"eligibility":{"minAge":"0 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Vomiting","Pyrexia","Nausea","Oedema peripheral","Pruritus"]}}